Skip to Main content Skip to Navigation
Journal articles

From ‘molecules of life’ to new therapeutic approaches, an evolution marked by the advent of artificial intelligence: the cases of chronic pain and neuropathic disorders

Abstract : The large families of the molecules of life are at the origin of the discovery of new compounds with which to treat disease. The arrival of artificial intelligence (AI) has considerably modified the search for innovative bioactive drugs and their therapeutic applications. Conventional approaches at different organizational research levels have emerged and, thus, AI associated with gene and cell therapies could supplant conventional pharmacotherapy and facilitate the diagnosis of pathologies. Using the examples of chronic pain and neuropathic disorders, which affect a large number of patients, I illustrate here how AI could generate new therapeutic approaches, why some compounds are seen as recreational drugs and others as medicinal drugs, and why, in some countries, psychedelic drugs are considered as potential therapeutic drugs but not in others.
Document type :
Journal articles
Complete list of metadata

https://hal-amu.archives-ouvertes.fr/hal-03142522
Contributor : Sébastien Poulain <>
Submitted on : Tuesday, February 16, 2021 - 10:10:15 AM
Last modification on : Wednesday, February 17, 2021 - 3:27:49 AM
Long-term archiving on: : Monday, May 17, 2021 - 6:36:41 PM

Files

DDT pub word final 27 01 2021...
Files produced by the author(s)

Licence


Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License

Identifiers

Collections

Citation

Jean-Louis Kraus. From ‘molecules of life’ to new therapeutic approaches, an evolution marked by the advent of artificial intelligence: the cases of chronic pain and neuropathic disorders. Drug Discovery Today Biosilico, Elsevier, 2021, ⟨10.1016/j.drudis.2021.01.009⟩. ⟨hal-03142522⟩

Share

Metrics

Record views

64

Files downloads

81